INDIANAPOLIS (AP) — The first non-stimulant drug designed to treat attention-deficit/hyperactivity disorder won approval Tuesday from the Food and Drug Administration.

Indianapolis-based Eli Lilly and Co. expects Strattera to be available in pharmacies in January.

Lilly has tested Strattera on more than 4,000 patients, some for as long as 2 1/2 years. It has not been tested in children under 6.

Strattera is the first drug to be approved for ADHD that is not a stimulant under the federal Controlled Substances Act. The drug comes in a capsule and can be taken once or twice a day. Lilly said it provides full-day relief from the symptoms of ADHD.

ADHD is one of the most common behavioral disorders of childhood. Although not widely recognized in adults, experts estimate that 4 percent, more than 8 million people, have the disorder, Lilly said.

Scientists believe it works by blocking or slowing reabsorption of norepinephrine, a brain chemical considered important in regulating attention, impulsiveness and activity levels.

The most common side effects of the drug are decreased appetite, nausea and vomiting.

In a separate decision, the FDA also approved Lilly's drug Forteo for treatment of osteoporosis. It is the first drug designed to stimulate the growth of new bone.